Tilray, a global pioneer in research, cultivation, production, and distribution of marijuana, has expanded its leadership team in Europe in order to drive global expansion.
The company has appointed former pharmaceutical leader from Grünenthal, Sascha Mielcarek, as its managing director, Europe. He was the Global Head of Gout Business Unit & Alliance Implementation Lead at Grünenthal.
Mielcarek has over 18 years of experience in the pharmaceutical industry. This includes extensive global commercial sales and marketing expertise in international markets such as the United States, Europe and Latin America.
“The expansion of our European senior leadership team strengthens Tilray’s ability to enter into new addressable markets and solidify our presence in existing European markets,” stated Tilray CEO Brendan Kennedy.
“Sascha brings an unmatched level of expertise from his years of experience in the European and global pharmaceutical industry and we’re very pleased to welcome him to our team”
As said in Tilray’s press release, as part of his new role, Mielcarek will “provide strategic leadership to Tilray’s existing European team as it pursues new market entries in Europe and continues to strengthen the company’s position in existing markets.”
Mielcarek and his team will also be “working collaboratively with Tilray’s team of experts at the state-of-the-art facility in Cantanhede, Portugal, which will act as the primary hub for the cultivation, processing, research and distribution of branded Tilray products throughout Europe, once fully licensed.”
Tilray has recently hired Greg Christopher as EVP of Operations, Rita Seguin as EVP of Human Resources, Dara Redler as General Counsel and Charlie Cain as VP of Retail. The company has already successfully exported within Europe to the following countries: Czech Republic, Germany, United Kingdom, Cyprus and Croatia, and outside of Europe to, Argentina, Chile, United States, South Africa, Australia and New Zealand.